A vial of lenacapavir, the new HIV prevention injectable drug that only needs to be administered twice yearly but provides almost complete protection. (Nardus Engelbrecht | AP)The U.S. announced Thursday that it will make an investment in the new HIV prevention drug called lenacapavir that’s been hailed as a “ breakthrough ” and a “ game changer ” by the medical community. Clinical trial results for the drug, lenacapavir, showed last year that twice-yearly injections can provide almost complete protection against contracting HIV for individuals at risk in their intimate relationships and for preventing mother-to-child transmission. In the past, PEPFAR has spearheaded efforts to introduce HIV prevention drugs — called pre-exposure prophylaxis or PrEP. “Prevention programs were absolutely gutted,” says Mitchell Warren , the executive director of AIDS Vaccine Advocacy Coalition (AVAC), an HIV prevention organization that works globally.